ReviewClinical chemistry2025
The Unique Utility of Newborn Dried Blood Spots for Driving Discovery in Childhood Cancer Research.
Review in Clinical chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundChildhood cancer, though rare, remains the leading cause of disease-related death among children in the United States. The overall incidence has been rising for the past several decades, and the factors underlying the increasing rates are unclear. This unexplained increase underscores the critical need for high-quality, well-powered epidemiologic research to elucidate causes and the natural history of childhood cancers. CONTENT: Newborn screening (NBS) utilizes dried blood spots collected soon after birth to identify serious, treatable conditions and enable timely intervention, testing over 98% of infants born in the United States annually. Some NBS programs allow for the retention and release of residual dried blood spots (rDBS) for research. rDBS enable population-based assessment of both endogenous and exogenous factors, including genetic, epigenetic, metabolic, immune characteristics, and environmental exposures during the perinatal period. This resource can overcome challenges of recall bias, exposure misclassification, and the impracticality of prospective cohort studies for rare cancers. Investigators have successfully used rDBS in epidemiologic studies, substantially advancing knowledge of several types of childhood cancers. Despite variability in storage and analyte stability, rDBS remain an invaluable resource to promote child health and constitute the only widely available prediagnostic biospecimen source for studies of childhood cancers. SUMMARY: rDBS from NBS programs represent a population-based, widely collected, prediagnostic biospecimen to investigate genetic, epigenetic, metabolic, and immune pathways underlying childhood cancer. Despite variability in storage policies, rDBS offer an unparalleled resource to advance etiologic understanding. Their integration into research could transform knowledge of childhood cancer causes and inform strategies for prevention and surveillance.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.